Daewoong to face biggest blow from price-cut plan

Daewoong Pharmaceutical Co. is likely to take a bigger blow from the government’s plan to slash drug prices starting April, Daeshin Securities said yesterday.

Daeshin said the loss of Daewoong’s sales is expected to post 79.7 billion won this year due to its heavy reliance of prescription drugs, followed by Dong-A Pharmaceutical with 62 billion won; Chong Kun Dang Pharmaceutical with 50.6 bi...